US Patent 11622959 Methods for treating heterotopic ossification
Patent 11622959 was granted and assigned to Clementia Pharmaceuticals Inc. on April, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 3 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Aug, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Clarissa Desjardins0
Donna Roy Grogan0
Jeffrey Neal Packman0
Mark Harnett0
Edits on 27 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 26 Apr, 2023
Golden AI
Infobox
Edits on 12 Apr, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+306 characters)
US Patent 11622959 Methods for treating heterotopic ossification
Article
The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116229590
Date of Patent
April 11, 2023
0Patent Application Number
169506040
Date Filed
November 17, 2020
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11622959 Methods for treating heterotopic ossification
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
